InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Discover the full record of transactions filed by Huizinga Robert Bindert, Vice-Président Exécutif. Officer active across 1 companies, notably Aurinia Pharmaceuticals Inc.. Aggregated, 11 reports have been published. Total volume traded: €322k. The latest transaction was disclosed on 2 March 2022 — Attribution. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations11 total
08,500 shares0
Common Stock
SEC:0001628280-22-005118:0·
€261,80595,000 shares@ €2.755846.9% of flow
Common Stock
SEC:0001628280-21-020527·
€261,80595,000 shares@ €2.75580.012% mcap23.4% of flow
Common Stock
SEC:0001628280-21-020527:0·
€35,89616,000 shares@ €2.24356.4% of flow
Common Stock
SEC:0001628280-21-019051·
€35,89616,000 shares@ €2.24350.0017% mcap3.2% of flow
Common Stock
SEC:0001628280-21-019051:0·
€83,8415,000 shares@ €16.768215.0% of flow
Common Stock
SEC:0001628280-21-018595·
€83,8415,000 shares@ €16.76820.0040% mcap7.5% of flow
Common Stock
SEC:0001628280-21-018595:0·
€77,2575,000 shares@ €15.451413.8% of flow
Common Stock
SEC:0001628280-21-018218·
€77,2575,000 shares@ €15.45140.0037% mcap6.9% of flow
Common Stock
SEC:0001628280-21-018218:0·
€99,46940,000 shares@ €2.486717.8% of flow
Common Stock
SEC:0001628280-21-009847·
€99,46940,000 shares@ €2.48670.0047% mcap8.9% of flow
Common Stock
SEC:0001628280-21-009847:0·
11 of 11 declarations
About Huizinga Robert Bindert
Robert Bindert Huizinga is the Executive Vice President of Research at Aurinia Pharmaceuticals Inc., a biopharmaceutical company. He is responsible for leading research and development initiatives aimed at innovating in the field of medical treatments.
